iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the chief executive officer directly owned 2,322,500 shares of the company’s stock, valued at approximately $191,931,400. This represents a 0.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

iRadimed Trading Up 3.1%

Shares of NASDAQ IRMD traded up $2.63 during midday trading on Tuesday, reaching $86.74. The company had a trading volume of 230,777 shares, compared to its average volume of 48,422. The stock has a market cap of $1.10 billion, a P/E ratio of 53.54 and a beta of 1.02. The business’s 50-day simple moving average is $73.39 and its 200 day simple moving average is $64.07. iRadimed Corporation has a 1 year low of $47.48 and a 1 year high of $87.88.

iRadimed Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, November 25th. Investors of record on Friday, November 14th will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, November 14th. iRadimed’s dividend payout ratio (DPR) is currently 41.98%.

Analyst Ratings Changes

Several research firms recently commented on IRMD. Lake Street Capital restated a “buy” rating and set a $100.00 price target on shares of iRadimed in a research report on Monday. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Roth Capital set a $90.00 target price on shares of iRadimed in a research report on Friday. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of iRadimed in a research report on Friday. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, iRadimed currently has an average rating of “Buy” and an average price target of $87.33.

Hedge Funds Weigh In On iRadimed

Several hedge funds and other institutional investors have recently modified their holdings of IRMD. First Horizon Advisors Inc. lifted its stake in shares of iRadimed by 78.7% in the first quarter. First Horizon Advisors Inc. now owns 513 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 226 shares in the last quarter. CWM LLC lifted its stake in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in shares of iRadimed in the third quarter worth about $47,000. Finally, Spire Wealth Management purchased a new position in shares of iRadimed in the second quarter worth about $60,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

iRadimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.